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OBJECTIVE: To perform an economical evaluation of
darunavir + low-dose ritonavir (DR) vs other protease inhibitors
(PIs) in treatment-experienced HIV-1-infected patients in the
Russian health care system. METHODS: The modeled study was
performed. A proportion of patients receiving alternative PIs,
dosing regimen, and efﬁcacy of drugs were extracted from mul-
ticenter randomized studies POWER 1 and 2 (Lancet 2007;
369:1169–78). The effect was measured in proportion of
patients with viral load reduction of 1 log 10 copies/ml or greater
from baseline and with viral load less than 50 copies/ml. Other
PIs in POWER studies were lopinavir + ritonavir, saquinavir,
amprenavir, atazanavir, indinavir, nelﬁnavir; all patients in both
groups received optimized background regimen. Cost of treat-
ment with PIs for 48 weeks and cost-effectiveness ratio (CER)
were calculated from the Russian reimbursement system point of
view. RESULTS: According to POWER studies, DR was much
more effective than other PIs (61 vs 15% of patients had viral
load reduction 1 log 10 copies/ml and 45 vs 10% achieved
viral load <50 copies/ml), while cost of treatment was a little
more for DR than other PIs (370,786.08 vs. 330,747.59 rubles or
15,105.64 vs USD 13,474.47). Incremental CER was 87,000
rubles (USD 3544.34) for one patient with viral load reduction
1 log 10 copies/ml and 114,400 rubles (USD 4660.60) for one
patient with viral load <50 copies/ml that seems reasonable for
expensive antiHIV treatment. CONCLUSION: According to the
model, DR seems to be much more effective than other PIs with
affordable CER incremental ratio. Evaluation of DR treatment
effectiveness and safety in common practice is needed.
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OBJECTIVE: Globally, an estimated 170 million persons are
chronically infected with hepatitis C virus (HNV) and 350
million—with hepatitis B (HBV). New HCV and HBV medicines
are 100%–400% more costly and have a negative impact on the
budget. The aim of this study was to calculate, in the health care
payer perspective, the cost effectiveness (CE) of new medicines
for HCV and HBV treatment in comparison with the previous
generation ones. METHODS: This analysis compares the CE of
entecavir, adefovir dipivoxil versus lamivudinum in previous
therapy refractory HBV patients and the CE of peginterferonum
alfa with interferonum alfa in chronic HCV patients. Data of
clinical effectiveness have been extracted from clinical studies
published in electronic databases (PubMed, Embase com,
Medscape, Cochrane Library) from 1990 to 2007 December.
Only direct medical costs (medicines) have been estimated. Costs
were based upon average wholesale price and State Reimburse-
ment list prices. A decision analytic model, made by TreeAge
DATA Professional program, has been used. RESULTS: The use
of new generation medicines, such as adefovir dipivoxil and
entecavir, is not cost effective for chronic HBV therapy in patients
with unsuccessful previous therapy due to high prices; however
the difference of effectiveness reaches 80%. Peginterferonum alfa
for chronic HCV compared with nonpegilated interferonum is
cost effective if the difference of effectiveness reaches 40% or the
shorter (12 week) course of pegilated interferon is needed. CON-
CLUSION: Despite the high medicines clinical effectiveness, the
new medicines are not cost effective compared with previous
generation for the chronic HCB and HBV treatment due to high
prices. Wherewith, the generic (cheaper?) medicines income to
the market is inescapable. Prospective studies including indirect
costs are necessary.
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OBJECTIVE: Candidemia is a nosocomial bloodstream infection
associated with considerable mortality and is costly to treat. A
new echinocandin, anidulafungin, has been shown to be effective
in treating candidemia and other forms of invasive candidiasis
(henceforth, candidemia). The objective of this study was to
compare cost and outcomes of anidulafungin with current
standard of care in Canada, and ﬂuconazole, for the treatment of
candidemia in non-neutropenic adult patients. METHODS: A
decision tree was constructed to examine the cost-effectiveness of
anidulafungin compared with ﬂuconazole, in the treatment of
candidemia. Data on treatment success, renal toxicity, duration
of intravenous and oral antifungal treatment, and patient sur-
vival were obtained from a published, randomized, double-blind
trial comparing anidulafungin with ﬂuconazole. Separate analy-
ses of the clinical trial data were performed to obtain length of
stay in the intensive care unit and general ward for each arm of
the trial. Therapy switching and additional resource use were
obtained from surveys of Canadian clinicians. Medical and drug
costs were taken from standard Canadian costing sources and
the published literature. The incremental cost per successfully
treated patient was calculated. Sensitivity analyses were per-
formed. RESULTS: The percentage of successfully treated
patients is higher for patients treated with anidulafungin than
with ﬂuconazole (74.02% vs. 56.78%). Treating with anidu-
lafungin results in higher antifungal drug costs $4792 vs. $2651;
however, overall costs are lower for treatment with anidulafun-
gin than for treatment with ﬂuconazole ($62,949 vs. $65,954,
respectively) due to an offset in other medical costs, mainly in
ICU where anidulafungin is associated with savings of $6707.
Thus, treating with anidulafungin is cost-savings (less costly and
more efﬁcacious) when compared to treating with ﬂuconazole.
CONCLUSION: Anidulafungin has demonstrated improved
clinical efﬁcacy versus standard of care in treating candidemia.
Despite an increase in drug costs, treating candidemia with
anidulafungin is a cost-saving strategy.
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OBJECTIVE: Limited information exists to guide clinicians in
selecting antibiotics for diabetic foot infections. Because this
serious complication causes substantial morbidity, mortality, and
incurs major health care costs, we developed a decision tree
model to determine, from the Ministry of Health’s perspective,
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the cost-effectiveness in Canada of the treatments recommended
by the Infectious Diseases Society of America guidelines for mild
diabetic foot infections. METHODS: A decision-tree model was
developed using TreeAge Pro-2007 and clinical experts. Success
probabilities were derived from published randomized controlled
trials. Drug costs were obtained from the 2007 Ontario Drug
Beneﬁt Formulary and McKesson Inc., and amputation costs
from CMG’s 2002/2003 database, with values adjusted to 2007
using the Canadian Consumer Price Index. Hospitalization costs
were obtained from Sunnybrook Hospital’s 2003/3004 database,
adjusted to 2007. One-way and two-way sensitivity analyses
were performed to test the robustness of the decision tree model
by varying the clinical success rates and costs of antibiotics.
Probabilistic sensitivity analyses were also performed using
Monte Carlo simulations. RESULTS: Clindamycin was cost-
effective, dominating all other choices, and cephalexin had
the next best proﬁle. Expected success rates were 99.4% for
clindamycin, 97.8% for cephalexin, 95.4% for amoxicillin-
clavulanate, 95.2% for cloxacillin and 95.0% for levoﬂoxacin.
The expected cost of clindamycin ($361.33) was substantially
lower than the next best alternative, cephalexin ($1239.99); a
cost difference of $878.66 per patient treated. However, success
rates were based on a single small trial for each drug (n < 30 for
each). In sensitivity analyses, the model/decision was sensitive to
changes in efﬁcacy rates and costs within plausible ranges for
clindamycin and cephalexin. CONCLUSION: Clindamycin was
cost-effective in treating mild diabetic foot infection but our
model had several limitations/assumptions; therefore, the results
should be interpreted cautiously. In general, few clinical studies
have evaluated oral antibiotics for treating these infections and
more are needed.
PIN23
PHARMACOECONOMIC ANALYSIS OF ANTIFUNGAL AGENTS
FORTHE MANAGEMENT OF NON NEUTROPENIC PATIENTS
WITH INVASIVE CANDIDIASIS ATTHE SOCIAL SECURITY
MEXICAN INSTITUTE (IMSS)
Contreras-Hernandez I1, Mould-Quevedo J2, Zendejas-Villanueva J1,
Guzmán-Sánchez J1, Rentería-Arellano MDC1, Davila-Loaiza G2,
Garduño-Espinosa J1
1Social Security Mexican Institute, Mexico City, Mexico, 2Pﬁzer Mexico,
Mexico City, Mexico
OBJECTIVE: Invasive candidiasis has become a frequent and a
high economic impact disease in Mexican hospitals. The purpose
of this study was to develop an economic assessment to evaluate
the cost-effectiveness between different antifungal agents for the
treatment of non neutropenic patients with invasive candidiasis
at the Social Security Mexican Institute (IMSS) from the payer’s
perspective. METHODS: A 12-week Bayesian decision-tree
model was performed to simulate costs and effectiveness out-
comes. Effectiveness measures were the rate of clinical success
without adverse events (AE) and the patient’s stay length in
intensive care units (ICU) at the end of the follow-up period.
Effectiveness data and transition probabilities were taken from
international published literature. The comparators were anidu-
lafungin (100 mg/day); liposomal amphotericin B (3 mg/kg/day);
amphotericin B (0.6 mg/kg/day); ﬂuconazol (200 mg/day);
caspofungin (initial dose 70 mg/day, subsequent 50 mg/day) and
voriconazol (400 mg/day). Resource use data and costs were
obtained from hospital records from one tertiary care hospital at
IMSS (n = 25). The model was calibrated according to interna-
tional pharmacoeconomics guidelines. One-way and probabilis-
tic sensitivity analyses were performed using Monte Carlo
Simulation second-order approach. RESULTS: Patients who
received anidulafungin experienced 58.8%(CI95%51.0%–
65.5%) of clinical success without AE, followed by limposomal
amphotericin B (46.7%[CI95%35.9%–61.6%]) and ﬂuconazol
(45%[CI95%37.8%–51.8%]). Patients treated with anidulafun-
gin were hospitalized with a mean of 15.4(CI95%8.5–22.2)
days in ICU followed by limposomal amphotericin B
(17.2[CI95%10.0–23.6]) and ﬂuconazol (17.5[CI95%10.8–
24.1]). Mean cost per patient were lower with anidulafungin
(US$32,711[CI95%US$29,720–US$36,456) followed by
limposomal amphotericin B (US$35,713[CI95%US$31,628–
US$39,660]) and ﬂuconazol (US$36,688[CI95%US$33,501–
US$40,402]). Based on ICERs, anidulafungin was the dominant
therapy. Acceptability curves and component analyses showed
anidulafungin as the most cost-effective therapy in a range of
80%–90% (p < 0.05). CONCLUSION: In Mexico, anidulafun-
gin was the most cost-effective antifungal therapy for invasive
candidiasis. These results should be taken into account by
Mexican decision makers in the management of non neutropenic
patients with invasive candidiasis.
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OBJECTIVE: Invasive candidiasis is a serious infectious disease
with high incidence and important economic impact due to its
long hospitalizations. The purpose of this study was to estimate
the cost-effectiveness of anidulafungin and other antifungal
agents in the management of invasive candidiasis in non-
neutropenic patients from the payer’s perspective. METHODS:
A Bayesian decision tree model allowing switches among differ-
ent antifungal treatments was performed. The model simulates
costs and effectiveness in a 12-week-period. Effectiveness mea-
sures were the rate of clinical success and percentage of survival.
Clinical efﬁcacy and transition probabilities were obtained from
published literature. Comparators were anidulafungin (100 mg/
day), amphotericin B (0.6 mg/kg/day) and ﬂuconazol (initial dose
400 mg/day, subsequent 200 mg/day). Resource use data and
costs were obtained from a tertiary care hospital “Hospital de
Especialidades” CMN Siglo XXI from the Social Security
Mexican Institute (n = 25). Resource use include: inpatient ser-
vices, intensive care unit, drugs and surgery. One-way sensitivity
analysis was performed and other probabilistic sensitivity
analyses were constructed. RESULTS: Patients treated with
anidulafungin experienced the higher clinical success (74.02%)
followed by amphotericin B (63.51%) and ﬂuconazol (56.78%).
On the other hand, anidulafungin yielded 77.17% of total-
survival followed by ﬂuconazol with 68.64% and amphotericin
B with 62.19%. The mean total costs per patient were
US$47,993 for anidulafungin; US$59,350 for ﬂuconazol and
US$60,349 for amphotericin B. ICERs estimated using amphot-
ericin B as the baseline strategy using clinical success as effec-
tiveness outcome were -US$117,633 for anidulafungin and
US$14,847 for ﬂuconazol. ICER’s estimated using the same com-
parator for total-survival as effectiveness was -US$82,503 for
anidulafungin and -US$15,482 for ﬂuconazol. Sensitivity analy-
ses showed that anidulafungin was the dominant strategy
(p < 0.05). CONCLUSION: In Mexico, anidulafungin treatment
was a cost-saving therapy not only because of its higher clinical
success and survival but for its potential cost reduction. These
results should be considered by Mexican decision-makers in
future cost-containment policies.
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